Insider Tracker SEC Form 4 insider trades
← All clusters
BLSM

BlossomHill Therapeutics, Inc.

AI summary Insiders and major institutional backers buy shares in BlossomHill Therapeutics' upsized $150 million initial public offering.

52
Insider Score Band below 60
Research score
63
AI adjustment
-11

Research score, not a recommendation.

Total bought$25.2M7 Form 4 purchases
Distinct insiders6open-market buyers
Lead insiderKeyes Jason ACFO
Cluster window2026-08-07 → 2026-08-10active

Market data

Live quote and chart from Yahoo Finance, loaded through this server. Insider purchases are marked on the chart.

–

partial data Price history is incomplete; missing inputs count as neutral in the score.

Why this score

Research score: a weighted blend of the five factors, times the routine and offering discounts, minus the selling penalty.

Breadth number & diversity of participating insiders
100%
Seniority executive rank of buyers (CEO/CFO/Director)
78%
Commitment purchase size relative to company & holdings
60%
Context buying into stock weakness signals conviction
50%
Timing coordinated purchases within a tight window
100%
Routine-purchase discount × 1.00
Company-type / offering discount × 0.50
Net insider selling penalty − 0

Why are they buying?

AI · ipo_offering · catalyst credible · documented

The purchases occurred concurrently with the closing of the company's initial public offering on August 10, 2026, where shares were priced at $16.00 following an upsized $150 million debut on Nasdaq.

Form 4 filings confirm that directors and officers, including representatives from major backers like OrbiMed and Cormorant, acquired shares directly as part of the initial public offering.

Stock Price & Insider Purchase History

Daily close price with open-market insider purchases plotted over time

Loading price history…

Transactions

7 Form 4 trades · 6 insiders Sign in to download CSV
Purchases in this cluster, grouped by insider, largest first
Date Insider Role Shares Price Value Flags Filing
2026-08-10 ORBIMED ADVISORS LLC history of ORBIMED ADVISORS LLC's purchases Director 625,000 $16.00 $10.0M
offering
SEC filing for ORBIMED ADVISORS LLC (opens in a new tab)
2026-08-10 GORDON CARL L history of GORDON CARL L's purchases Director 625,000 $16.00 $10.0M
offering
SEC filing for GORDON CARL L (opens in a new tab)
2026-08-10 Chen Bihua history of Chen Bihua's purchases Director 312,500 $16.00 $5.0M
offering
SEC filing for Chen Bihua (opens in a new tab)
2026-08-10 Schmid John P. history of Schmid John P.'s purchases Director 6,000 $16.00 $96.0K
offering
SEC filing for Schmid John P. (opens in a new tab)
2026-08-07 → 2026-08-10 Liptak Vincent Paul history of Liptak Vincent Paul's purchases General counsel 4,700 $15.89 avg $74.7K
offering
2026-08-07 Liptak Vincent Paul 2,500 $15.80 $39.5K
SEC filing for Liptak Vincent Paul (opens in a new tab)
2026-08-10 Liptak Vincent Paul 2,200 $16.00 $35.2K
offering
SEC filing for Liptak Vincent Paul (opens in a new tab)
2026-08-10 Keyes Jason A history of Keyes Jason A's purchases CFO 700 $16.00 $11.2K
offering
SEC filing for Keyes Jason A (opens in a new tab)
Total $25.2M

What happened next

A run ends after a pause in the buying, so one company can have several. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.

After this run became a cluster: 21 days +33.4%63 days –126 days –